Background: The slow coronary flow (SCF) phenomenon is a coronary microvascular disorder characterized by the delayed passage of contrast in the absence of obstructive epicardial coronary disease. Recent studies showed the possible role of endothelial dysfunction, diffuse atherosclerosis and inflammation in the pathogenesis of this phenomenon. We aimed to investigate the effect of statin on myocardial perfusion in patients with SCF. Methods and Results: The study population consisted of 97 patients with SCF. Coronary flow patterns of the cases are determined by thrombolysis in myocardial infarction (TIMI) frame count method. Single-photon emission computed tomographic myocardial perfusion imaging studies and lipid parameters of the patients were obtained before and after 6 months of simvastatin treatment period. During the study, daily single dose of 40 mg simvastatin has been given to each subject. We found a significant positive correlation between mean TIMI frame count and basal reversibility score (r = 0.84, p = 0.0001). In addition, analysis of the reversibility scores demonstrates that simvastatin treatment has significantly improved the myocardial perfusion abnormality at the end of the follow-up period. Conclusion: Present findings allow us to conclude that simvastatin improved myocardial perfusion in patients with SCF.

Keywords:
Slow coronary flow, TIMI frame count, Myocardial ischemia, Endothelial function, Atherosclerosis, Statin
1.
Tambe AA, Demany MA, Zimmerman HA, Masearanhas E: Angina pectoris and slow flow velocity of dye in coronary arteries, a new angiographic finding. Am Heart J 1972;84:66–71.
2.
Mosseri M, Yarom R, Gotsman MS, Hasin Y: Histologic evidence for small-vessel coronary artery disease in patients with angina and patent large coronary arteries. Circulation 1986;74:964–972.
3.
Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, et al: Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996;37:375–381.
4.
Ciavolella M, Avella A, Bellagamba S, Mangieri E, Nigri A, Reale A: Angina and normal epicardial coronary arteries radionuclide features and pathophysiological implications at long term follow up. Coron Artery Dis 1994;5:493–499.
5.
Cesar LAM, Ramires JAF, Serrano CV Jr, Meneghetti JC, Antonelli RH, da-Luz PL, et al: Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. Braz J Med Biol Res 1996;29:605–613.
6.
Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al: TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879– 888.
7.
Kaul S, Finkelstein DM, Homma S, Leavitt M, Okada RD, Boucher CA: Superiority of quantitative exercise thallium–201 variables in determining long-term prognosis in ambulatory patients with chest pain: a comparison with cardiac catheteterization. J Am Coll Cardiol 1998;12:25–34.
8.
Kemp HG, Elliott W, Gorlin RD: The anginal syndrome with normal coronary arteriography. Trans Assoc Am Physicians 1967;80:59.
9.
Kurtoglu N, Akcay A, Dindar I: Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol 2001;87:777–779.
10.
Camsari A, Pekdemir H, Cicek D, Polat G, Akkus MN, Doven O, et al: Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003;67:1022–1028.
11.
Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al: Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003;14:155–161.
12.
Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Doven O, et al: Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol 2004;59:127–133.
13.
Chilian WM, Layne SM, Klausher EC, Eastham CL, Marcus ML: Redistribution of coronary microvascular resistance produced by dipyridamole. Am J Physiol 1989;256:383–390.
14.
Zeiher AM, Schachinger V, Hohnloser SH, Saurbier B, Just H: Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525–2532.
15.
Tanriverdi H, Evrengul H, Enli Y, Kuru O, Seleci D, Tanriverdi S, et al: Effect of homocysteine induced oxidative stress on endothelial function in coronary slow flow. Cardiology 2007;107:313–320.
16.
Tanriverdi H, Evrengul H, Tanriverdi S, Kuru O, Seleci D, Enli Y, et al: Carotid intima media thickness in coronary slow flow; relationship with plasma homocysteine levels. Coron Artery Dis 2006;17:331–337.
17.
Demirkol MO, Yaymacı B, Mutlu B: Dipyridamole myocardial perfusion single photon emission computed tomography in patients with slow coronary flow. Coron Artery Dis 2002;13:223–229.
18.
Turhan H, Saydam GS, Erbay AR, Ayaz S, Yasar AS, Aksoy Y, et al: Increased plas ma soluble adhesion molecules: ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol 2005;98:450–456.
19.
NairP, Roguin A: Statins and the acute coronary syndrome: ‘the early bird catches the worm’. Int J Clin Pract 2006;60:716–727.
20.
Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G: Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003;93:98–103.
21.
Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995;346:467–471.
22.
Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300–305.
23.
Girona J, La Ville AE, Sola R, Plana N, Masana L: Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846–851.
24.
Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, et al: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719–725.
25.
Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711–2719.
26.
Sarkar K, Sinha AK, Mehta JL: The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol 206; 21:316–321.
27.
Dupuis J, Tardif JC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227–3233.
28.
Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447–1452.
29.
Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein. Circulation 2001;103:1933–1935.
30.
Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212–1217.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.